- Home
- CRON vs GERN Comparison
CRON vs GERN Comparison
Compare CRON & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRON
- GERN
- Stock Information
- Founded
- CRON N/A
- GERN 1990
- Country
- CRON Canada
- GERN United States
- Employees
- CRON N/A
- GERN N/A
- Industry
- CRON Medicinal Chemicals and Botanical Products
- GERN Biotechnology: Pharmaceutical Preparations
- Sector
- CRON Health Care
- GERN Health Care
- Exchange
- CRON Nasdaq
- GERN Nasdaq
- Market Cap
- CRON 809.4M
- GERN 893.2M
- IPO Year
- CRON N/A
- GERN 1996
- Fundamental
- Price
- CRON $2.50
- GERN $1.40
- Analyst Decision
- CRON
- GERN Buy
- Analyst Count
- CRON 0
- GERN 8
- Target Price
- CRON N/A
- GERN $3.71
- AVG Volume (30 Days)
- CRON 4.2M
- GERN 8.0M
- Earning Date
- CRON 08-07-2025
- GERN 08-06-2025
- Dividend Yield
- CRON N/A
- GERN N/A
- EPS Growth
- CRON N/A
- GERN N/A
- EPS
- CRON 0.05
- GERN N/A
- Revenue
- CRON $130,282,000.00
- GERN $164,447,000.00
- Revenue This Year
- CRON $19.67
- GERN $175.15
- Revenue Next Year
- CRON $30.56
- GERN $56.61
- P/E Ratio
- CRON $52.23
- GERN N/A
- Revenue Growth
- CRON 28.01
- GERN 11877.20
- 52 Week Low
- CRON $1.60
- GERN $1.09
- 52 Week High
- CRON $2.77
- GERN $4.83
- Technical
- Relative Strength Index (RSI)
- CRON 55.55
- GERN 51.31
- Support Level
- CRON $2.47
- GERN $1.40
- Resistance Level
- CRON $2.71
- GERN $1.52
- Average True Range (ATR)
- CRON 0.11
- GERN 0.07
- MACD
- CRON -0.02
- GERN -0.01
- Stochastic Oscillator
- CRON 36.70
- GERN 21.05
About CRON Cronos Group Inc. Common Share
Cronos Group Inc headquartered in Toronto, Canada, cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis primarily to Israel. In the U.S., the company has an option to acquire 5.9% of U.S. multistate operator PharmaCann on a fully diluted basis upon easing of federal prohibition.
About GERN Geron Corporation
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.